Patents by Inventor Pinchas Cohen

Pinchas Cohen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210371479
    Abstract: Described herein is a novel, mitochondrial encoded, open reading frame, that leads to the production of a new mitochondrial peptide. Residing within the ND-Two subunit, a specific small nucleotide polymorphism disrupts expression of this mitochondrial peptide, and is correlated with an increase in obesity and diabetes, particularly in certain ethnic populations. In vitro administration of the peptide increases insulin secretion, decreases fat accumulation and improves glucose uptake in muscle cell. Antibodies generated against the peptide can be used for detecting peptide deficiency, in addition to SNP detection, supporting diagnostic approaches. In vivo studies further revealed that administration of the peptide improves glucose tolerance, thereby providing a new therapeutic avenue for a novel diabetes therapy and decreases bodyweight, thus serving as a novel obesity therapy. Generation of synthetic analogs further enhance or abrogated activity relative to the natural peptide.
    Type: Application
    Filed: August 4, 2021
    Publication date: December 2, 2021
    Applicant: University of Southern California
    Inventors: Pinchas COHEN, Kelvin YEN
  • Publication number: 20210332141
    Abstract: The present disclosure provides a method of improvement, preservation, prophylaxis, or inhibition-of-deterioration of a healthspan parameter of a mammalian subject. In exemplary embodiments, the method comprises administering to the subject a composition that comprises an insulin-like growth factor-1 receptor (IGF-1 R) inhibitor, wherein the composition is administered in an amount effective to improve, provide prophylaxis for, or inhibit-the-deterioration of the healthspan parameter.
    Type: Application
    Filed: August 30, 2018
    Publication date: October 28, 2021
    Inventors: Pedro Beltran, Derek Huffman, Nir Brazilal, Pinchas Cohen
  • Patent number: 11124551
    Abstract: Described herein is a novel, mitochondrial encoded, open reading frame, that leads to the production of a new mitochondrial peptide. Residing within the ND-Two subunit, a specific small nucleotide polymorphism disrupts expression of this mitochondrial peptide, and is correlated with an increase in obesity and diabetes, particularly in certain ethnic populations. In vitro administration of the peptide increases insulin secretion, decreases fat accumulation and improves glucose uptake in muscle cell. Antibodies generated against the peptide can be used for detecting peptide deficiency, in addition to SNP detection, supporting diagnostic approaches. In vivo studies further revealed that administration of the peptide improves glucose tolerance, thereby providing a new therapeutic avenue for a novel diabetes therapy and decreases bodyweight, thus serving as a novel obesity therapy. Generation of synthetic analogs further enhance or abrogated activity relative to the natural peptide.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: September 21, 2021
    Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Pinchas Cohen, Kelvin Yen
  • Patent number: 10391143
    Abstract: MOTS3 is a novel polypeptide. Methods of treating diseases such as diabetes, obesity, fatty liver, and cancer using MOTS3 and pharmaceutical compositions thereof are disclosed herein.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: August 27, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Pinchas Cohen, Changhan Lee
  • Publication number: 20190194275
    Abstract: Described herein is a novel, mitochondrial encoded, open reading frame, that leads to the production of a new mitochondrial peptide. Residing within the ND-Two subunit, a specific small nucleotide polymorphism disrupts expression of this mitochondrial peptide, and is correlated with an increase in obesity and diabetes, particularly in certain ethnic populations. In vitro administration of the peptide increases insulin secretion, decreases fat accumulation and improves glucose uptake in muscle cell. Antibodies generated against the peptide can be used for detecting peptide deficiency, in addition to SNP detection, supporting diagnostic approaches. In vivo studies further revealed that administration of the peptide improves glucose tolerance, thereby providing a new therapeutic avenue for a novel diabetes therapy and decreases bodyweight, thus serving as a novel obesity therapy. Generation of synthetic analogs further enhance or abrogated activity relative to the natural peptide.
    Type: Application
    Filed: June 23, 2017
    Publication date: June 27, 2019
    Applicant: University of Southern California
    Inventors: Pinchas Cohen, Kelvin Yen
  • Publication number: 20180360910
    Abstract: MOTS3 is a novel polypeptide. Methods of treating diseases such as diabetes, obesity, fatty liver, and cancer using MOTS3 and pharmaceutical compositions thereof are disclosed herein.
    Type: Application
    Filed: August 27, 2018
    Publication date: December 20, 2018
    Inventors: Pinchas Cohen, Changhan Lee
  • Patent number: 10064914
    Abstract: MOTS3 is a novel polypeptide. Methods of treating diseases such as diabetes, obesity, fatty liver, and cancer using MOTS3 and pharmaceutical compositions thereof are disclosed herein.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: September 4, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Pinchas Cohen, Changhan Lee
  • Publication number: 20170049853
    Abstract: MOTS3 is a novel polypeptide. Methods of treating diseases such as diabetes, obesity, fatty liver, and cancer using MOTS3 and pharmaceutical compositions thereof are disclosed herein.
    Type: Application
    Filed: May 4, 2016
    Publication date: February 23, 2017
    Inventors: Pinchas COHEN, Changhan LEE
  • Publication number: 20140296139
    Abstract: MOTS3 is a novel polypeptide. Methods of treating diseases such as diabetes, obesity, fatty liver, and cancer using MOTS3 and pharmaceutical compositions thereof are disclosed herein.
    Type: Application
    Filed: March 14, 2014
    Publication date: October 2, 2014
    Inventors: Pinchas COHEN, Changhan LEE, Laura J. COBB
  • Publication number: 20140213527
    Abstract: Novel peptides referred to as small humanin-like peptides (SHLPs) are provided herein along with nucleic acids encoding SHLPs and probes that selectively bind SHLPs. SHLPs have wide-ranging activity, including neuroprotective activity, anticancer activity, and cell survival activity. Also provided herein are therapeutic methods comprising administering an effective amount of an SHLP to a subject in need of treatment.
    Type: Application
    Filed: December 19, 2013
    Publication date: July 31, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Pinchas COHEN, Laura J. Cobb
  • Patent number: 8653027
    Abstract: The present invention is based on the discovery that Humanin and humanin analogues protect pancreatic beta cells in vitro and in vivo from apoptosis. Accordingly, humanin and its analogues are useful for preventing and treating diabetes and promoting beta cell survival in a number of applications.
    Type: Grant
    Filed: July 11, 2011
    Date of Patent: February 18, 2014
    Assignee: The Regents of the University of California
    Inventors: Pinchas Cohen, Kuk-Wha Lee
  • Patent number: 8637470
    Abstract: Novel peptides referred to as small humanin-like peptides (SHLPs) are provided herein along with nucleic acids encoding SHLPs and probes that selectively bind SHLPs. SHLPs have wide-ranging activity, including neuroprotective activity, anticancer activity, and cell survival activity. Also provided herein are therapeutic methods comprising administering an effective amount of an SHLP to a subject in need of treatment.
    Type: Grant
    Filed: May 1, 2009
    Date of Patent: January 28, 2014
    Assignee: The Regents of the University of California
    Inventors: Pinchas Cohen, Laura J. Cobb
  • Publication number: 20130123168
    Abstract: The present invention is directed to methods and compositions for preventing or reducing atherosclerotic lesions and plaques. Specifically, the instant invention provides methods for using humanin and its analogues to prevent or reduce the formation of atherosclerotic plaques. Also provided are methods of using humanin and its analogues to improve the survival of endothelial cells, particularly aortic endothelial cells.
    Type: Application
    Filed: June 18, 2012
    Publication date: May 16, 2013
    Applicant: The Regents of the University of California
    Inventors: Pinchas Cohen, Amir Lerman, Lilach O. Lerman
  • Publication number: 20130045916
    Abstract: Provided are methods of using humanin and humanin analogs to treat a mammal exhibiting or at risk for insulin resistance, increase insulin sensitivity in a mammal exhibiting or at risk for insulin resistance, treat type-2 diabetes mellitus, metabolic syndrome, and neurodegeneration, treat and prevent myocardial injury, and determine longevity.
    Type: Application
    Filed: October 9, 2012
    Publication date: February 21, 2013
    Applicants: The Regeants of the University of California, Albert Einstein College of Medicine of Yeshiva University
    Inventors: Nir Barzilai, Pinchas Cohen, Radhika Muzumdar, David Lefer
  • Patent number: 8309525
    Abstract: Provided are methods of using humanin and humanin analogs to treat a mammal exhibiting or at risk for insulin resistance, increase insulin sensitivity in a mammal exhibiting or at risk for insulin resistance, treat type-2 diabetes mellitus, metabolic syndrome, and neurodegeneration, treat and prevent myocardial injury, and determine longevity.
    Type: Grant
    Filed: May 28, 2008
    Date of Patent: November 13, 2012
    Assignees: Albert Einstein College of Medicine of Yeshiva University, The Regents of the University of California
    Inventors: Nir Barzilai, Pinchas Cohen, Radhika Muzumdar
  • Publication number: 20120021981
    Abstract: The present invention is based on the discovery that Humanin and humanin analogues protect pancreatic beta cells in vitro and in vivo from apoptosis. Accordingly, humanin and its analogues are useful for preventing and treating diabetes and promoting beta cell survival in a number of applications.
    Type: Application
    Filed: July 11, 2011
    Publication date: January 26, 2012
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: PINCHAS COHEN, KUK-WHA LEE
  • Patent number: 7998928
    Abstract: The present invention is based on the discovery that Humanin and humanin analogues protect pancreatic beta cells in vitro and in vivo from apoptosis. Accordingly, humanin and its analogues are useful for preventing and treating diabetes and promoting beta cell survival in a number of applications.
    Type: Grant
    Filed: September 15, 2008
    Date of Patent: August 16, 2011
    Assignee: The Regents of the University of California
    Inventors: Pinchas Cohen, Kuk-Wha Lee
  • Publication number: 20110039771
    Abstract: Novel peptides referred to as small humanin-like peptides (SHLPs) are provided herein along with nucleic acids encoding SHLPs and probes that selectively bind SHLPs. SHLPs have wide-ranging activity, including neuroprotective activity, anticancer activity, and cell survival activity. Also provided herein are therapeutic methods comprising administering an effective amount of an SHLP to a subject in need of treatment.
    Type: Application
    Filed: May 1, 2009
    Publication date: February 17, 2011
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Pinchas Cohen, Laura J. Cobb
  • Publication number: 20100204099
    Abstract: Provided are methods of using humanin and humanin analogs to treat a mammal exhibiting or at risk for insulin resistance, increase insulin sensitivity in a mammal exhibiting or at risk for insulin resistance, treat type-2 diabetes mellitus, metabolic syndrome, and neurodegeneration, treat and prevent myocardial injury, and determine longevity.
    Type: Application
    Filed: May 28, 2008
    Publication date: August 12, 2010
    Inventors: Nir Barzilai, Pinchas Cohen, Radhika Muzumdar, David Lefer
  • Publication number: 20100130412
    Abstract: The present invention is based on the discovery that Humanin and humanin analogues protect pancreatic beta cells in vitro and in vivo from apoptosis. Accordingly, humanin and its analogues are useful for preventing and treating diabetes and promoting beta cell survival in a number of applications.
    Type: Application
    Filed: September 15, 2008
    Publication date: May 27, 2010
    Applicant: The Regents of the University of California
    Inventors: Pinchas Cohen, Kuk-Wha Lee